FOI Reference: FOI 422 – 2021

Title: Research on the treatment of

Date: March 2021

FOI Category: Pharmacy

FOI Request:

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

• • Carboplatin with Gemcitabine • Carboplatin with Paclitaxel • Carboplatin single or in any other combination • Cisplatin with Gemcitabine • Cisplatin single or in any other combination • • MVAC with G-CSF • • Any other regimen including Paclitaxel • Any other chemo regimen • Other active systemic anti-cancer therapy [please state] • Palliative care only

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

• Total non-small cell lung cancer (NSCLC) • BRAF+ non-small cell lung cancer (NSCLC)

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

• • • Atezolizumab + + Carboplatin + Paclitaxel • Atezolizumab monotherapy • Bevacizumab • • • • • Dabrafenib with • Docetaxel •

[Type text]

• • • Gemcitabine • with Docetaxel • Nivolumab • • Paclitaxel • Pembrolizumab chemo in combination • Pembrolizumab monotherapy • Pemetrexed with Carboplatin • Pemetrexed with Cisplatin • Vinorelbine and cisplatin/carboplatin

FOI Response:

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

Atezolizumab 0 Carboplatin with Gemcitabine <5 Carboplatin with Paclitaxel 0 Carboplatin single or in any other combination 0 Cisplatin with Gemcitabine 0 Cisplatin single or in any other combination 0 Nivolumab 0 MVAC with G-CSF 0

Pembrolizumab <5 Any other regimen including Paclitaxel 0 Any other chemo regimen 0 Other active systemic anti-cancer therapy [please state] 0 Palliative care only 0

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

Total non-small cell lung cancer (NSCLC) 43 BRAF+ non-small cell lung cancer (NSCLC) 0

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

Afatinib 0 Alectinib <5 Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0 [Type text]

Atezolizumab monotherapy <5 Bevacizumab 0 Brigatinib 0 Ceritinib 0 Crizotinib 0 Dacomitinib 0 Dabrafenib with Trametinib 0 Docetaxel 0 Durvalumab <5 Erlotinib <5 Gefitinib 0 Gemcitabine <5 Nintedanib with Docetaxel <5 Nivolumab 0 Osimertinib <5 Paclitaxel 0 Pembrolizumab chemo in combination 0 Pembrolizumab monotherapy 10 Pemetrexed with Carboplatin 9 Pemetrexed with Cisplatin 0 Vinorelbine and cisplatin/carboplatin <5

Additional Information/Documents:

The Trust has suppressed some of the numbers within our response as it relates to a small geographical area and due to the low numbers of individuals involved. We are unable to provide the information requested as it constitutes personal data relating to an identifiable individual, disclosure of which would be in contravention of the principles set out in EU General Data Protection Regulations 2016 (GDPR) and UK Data Protection Act 2018 (DPA).

In particular, Principle (a) states that: Personal data shall be processed lawfully, fairly and in a transparent manner in relation to individuals and in particular, shall not be processed unless at least one of the lawful bases for processing set out in Article 6 GDPR is met and in the case of special category personal data, at least one of the lawful bases for processing set out in Article 9 GDPR is met. In this case, the Trust, as a public authority, is under a legal obligation (Article 6(1) (c) GDPR to process the information to ensure it complies with its statutory obligations under the Freedom of Information Act. However, the Trust does not have a lawful basis to process the requested special category personal data under Article 9 GDPR and it is considered that disclosure would not be lawful or in line with Principle (a) for the following specified reasons:  the information relates to a small geographical area  disclosure, given the sensitivity of the information, could cause significant distress to those involved  individuals have a reasonable level of expectation that their personal medical information provided in confidence will not be disclosed [Type text]

 disclosure of the information and descriptions broken down as requested could enable them (or their close contacts/families) to self-identify the individual from that data. After due consideration given to this matter, we therefore decline to disclose the information as requested, applying the exemption under sections 40 (2) and 40 (3) (a) (i) of the Freedom of Information Act 2000.

[Type text]